A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

por Armand, Philippe, Lesokhin, Alexander, Borrello, Ivan, Timmerman, John, Gutierrez, Martin, Zhu, Lili, Popa McKiver, Mihaela, Ansell, Stephen M.
Publicado 2020

Sensitive multiple myeloma disease monitoring by mass spectrometry

por Santockyte, Rasa, Jin, Chelsea, Pratt, James, Ammar, Ron, Desai, Keyur, Bolisetty, Mohan, Das, Prianka, Popa-McKiver, Mihaela, Puig, Oscar
Publicado 2021

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

por Dimopoulos, Meletios A., Dytfeld, Dominik, Grosicki, Sebastian, Moreau, Philippe, Takezako, Naoki, Hori, Mitsuo, Leleu, Xavier, LeBlanc, Richard, Suzuki, Kenshi, Raab, Marc S., Richardson, Paul G., Popa McKiver, Mihaela, Jou, Ying-Ming, Yao, David, Das, Prianka, San-Miguel, Jesús
Publicado 2023